课题基金 / 基金详情

PHASE II PLACEBO CONTROLLED TRIAL OF RECOMBINANT HUMAN GM CSF

PHASE II PLACEBO CONTROLLED TRIAL OF RECOMBINANT HUMAN GM CSF
重组人类 GM CSF 的 II 期安慰剂对照试验
批准号：
6117838
负责人：
JOSEPH WHEAT
金额：
$1.7万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6117838
关键词：
HIV infections antiviral agents clinical research colony stimulating factor drug screening /evaluation health economics human morbidity human mortality human subject human therapy evaluation opportunistic infections pathologic process placebos quality of life

项目摘要

项目成果

JOSEPH WHEAT的其他基金

相似基金

相关文献

中文摘要
翻译
主要目的是比较机会性 晚期HIV感染患者中GM-CSF或安慰剂的感染 在标准抗逆转录病毒治疗的背景下。 第二个目标是比较新发或复发艾滋病的时间- 相关临床事件，包括机会性感染和 恶性肿瘤;比较生存期;比较药物经济学和质量 生命参数;以确定发生和临床 在患者人群中GM-CSF引起HIV上调的意义 接受抗逆转录病毒治疗
英文摘要
The primary objective is to compare the incidence of opportunistic infections with GM-CSF or placebo in patients with advanced HIV infection against a background of standard antiretroviral therapy. The secondary objective is to compare the time to new or recurrent AIDS- related clinical events including opportunistic infections and malignancies; to compare survival; to compare pharmacoeconomic and quality of life parameters; to determine the occurrence of and clinical siginficance of HIV- up-regulation due to GM-CSF in a patient population receiving antiretroviral therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AMBISOME VS AMPHOTERICIN B FOLLOWED BY FLUCONAZOLE IN TREATMENT OF MENINGITIS
CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA
PHASE II TRIAL OF MEGESTROL ACETATE AND TESTOSTERONE
CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA
海外基金